INTRODUCTION
============

The primary objective of oncological treatments, such as chemotherapy, is to destroy cancer cells. However, most chemotherapeutic agents do not act selectively, *i.e* particularly fast-growing cells, such as gastrointestinal, capillary, and immune cells.^(^ [@B1] ^-^ [@B3] ^)^ The toxicity of chemotherapeutic agents is known to be associated with the mode of action, dose and interaction between different agents in a given protocol.^(^ [@B4] ^,^ [@B5] ^)^

Oral mucositis (OM) is an important adverse effect seen in cancer patients on chemotherapy and/or radiation therapy for the head and neck.^(^ [@B2] ^,^ [@B6] ^,^ [@B7] ^)^ This condition presents clinically as erosive and/or ulcerative lesions that can cause mild to severe pain.^(^ [@B1] ^,^ [@B2] ^,^ [@B8] ^)^ These lesions usually lead to a significant decrease in quality of life, since they can prolong hospital stay, affect the nutritional status of the patient, increase the risk of infections, and increase the prescription of opioids.^(^ [@B9] ^-^ [@B11] ^)^

For these reasons, treatment of OM is extremely necessary, with the aim of relieving symptoms, accelerating tissue repair and controlling infections of oral origin. Currently, efforts are focused on preventing OM. The Mucositis Study Group of the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology (MASCC/ISOO) has published guidelines^(^ [@B12] ^)^ to orient the clinical practice for prevention/treatment of this condition. In these guidelines, preventive measures for OM are described without specification of the chemotherapy protocol used.

The known association between toxicity and the chemotherapy protocol used may guide selection of the right prevention methods to control OM in highrisk populations.

OBJECTIVE
=========

To review the scientific production on severity of oral mucositis as an adverse effect of different chemotherapy protocols.

METHODS
=======

An integrative review with data gathered from multiple articles to assist in understanding how different chemotherapy protocols can trigger mild or severe degrees of OM. In the field of health, the amount of information is ever growing, and evidencebased practice has become a must. In this way, the methodology of integrative reviews aims to synthesize knowledge to be incorporated in the practice by identifying independent studies on the same subject and analyzing their results.

This review was based on a search at PubMed databases. The search was started and completed in May 2016. Studies published in English, Spanish or Portuguese were selected for analysis. There were no restrictions regarding the year of publication and the studies retrieved were published before May 2016. After the search, the articles were selected according to their inclusion and exclusion criteria. The search strategy was based on a combination of the keywords "oral mucositis" and "chemotherapy protocols".

The inclusion criteria were original articles with open access to the full text, whose study subjects were patients diagnosed with OM after chemotherapy. Case reports, clinical trials, and literature reviews were excluded, as well as articles that did not describe the outcomes of the chemotherapy-associated OM.

Study identification, selection and inclusion
---------------------------------------------

Data collection was carried out by an independent researcher. After applying the search strategy with the keywords defined, the articles were selected. First the titles were read, and those that clearly did not meet the inclusion criteria for this review were readily excluded. Next, the abstracts of the selected articles were read and just like we did with the titles, the articles that clearly did not meet the predefined inclusion criteria of this review were excluded. Finally, all studies not excluded after these first two steps were read in full, and finally selected those to be included in this review.

Key data for each article were collected and entered into the database of the software Microsoft^®^ Excel^®^ for Mac 2011. The variables considered were journal, year/place, design, sample, protocol used and incidence of OM.

RESULTS
=======

Using the keywords of choice, 547 articles were retrieved. Of those, 325 articles were excluded by the title, 173 by the abstract and 23 by the full text, which left us with 26 articles.

The 26 articles selected were in English, published between 1987 and 2015, and the largest number of studies was from the last 5 years (n=8). All articles were original, including 24 prospective and only two retrospective studies. Of the 26 articles, only two aimed to evaluate severity of OM triggered by a given chemotherapy protocol. The other 24 studies focused on treatment efficacy and safety, and just reported the incidence of OM.

[Table 1](#t1){ref-type="table"} displays the sample of each study, the chemotherapy protocol used and the severity of OM developed in each protocol. The median number of subjects assessed in each article was 135 (minimum 16 and maximum 716). The mean age of participants was 43.54 years (minimum 5.2 years and maximum 65 years).

###### Distribution of protocols used in each study and severity of oral mucositis

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Article                       Sample                                         Protocol                                                         Severity of mucositis
  ----------------------------- ---------------------------------------------- ---------------------------------------------------------------- -----------------------------------
  Chibaudel et al.,([@B13])     42 patients\                                   Cetuximab (IV) D1, 8 and 15\                                     G0 = 27 (65.8%)\
                                Mean age: 56 years\                            Cisplatin D1, 8 and 15\                                          G1 = 5 (12.2%)\
                                Oropharyngeal carcinoma                        5-FU 750mg/m^2^ D1-5                                             G2 = 4 (9.8%)\
                                                                                                                                                G3 = 5 (12.2%)\
                                                                                                                                                G4 = 0

  Bano et al.,([@B14])          38 patients\                                   Protocol 1 - FOLFOX 4\                                           Protocol 1 - G0 = 24%\
                                Mean age: 61 years\                            - Oxaliplatin 85mg/m^2^ (IV) D1\                                 G1 and 2= 65%\
                                Colorectal carcinoma\                          - 5-FU 400mg/m^2^ IV bolus + 600mg/m^2^ continuous D1 and 2\     G3 and 4 = 11%\
                                Protocol 1 = 13 patients\                      - Leucovorin 200mg/m^2^ D1 and 2\                                \
                                Protocol 2 = 12 patients\                      Protocol 2 - FOLFOX 6\                                           Protocol 2 - G0 = 38%\
                                Protocol 3 = 5 patients\                       - Oxaliplatin 100mg/m^2^ (IV) D1\                                G1 and 2 = 56%\
                                Protocol 4 = 8 patients                        - 5-FU 400mg/m^2^ IV bolus + 2,400mg/m^2^ continuous D1 and 2\   G3 and 4 = 6%\
                                                                               - Leucovorin 400mg/m^2^ D1 and 2\                                \
                                                                               Protocol 3 - mFOLFOX 6\                                          Protocol 3 - G0 = 21%\
                                                                               - Oxaliplatin 100mg/m^2^ (IV) D1\                                G1 and 2 = 79%\
                                                                               - 5-FU 2,000mg/m^2^ continuous D1 and 2\                         G3 and 4 = 0\
                                                                               - Leucovorin 100mg/m^2^ D1 and 2\                                \
                                                                               Protocol 4 - FOLFOX 7\                                           Protocol 4 - G0 = 7%\
                                                                               - Oxaliplatin 130mg/m^2^ (IV) D1\                                G1 and 2 = 90%\
                                                                               - 5-FU 2,400mg/m^2^ continuous D1 and 2\                         G3 and 4 = 3%
                                                                               - Leucovorin 400mg/m^2^ D1 and 2                                 

  Wang et al.,([@B15])          65 patients\                                   Cisplatin 50mg/m^2^ (IV) D1\                                     G0 = 3.1%\
                                Mean age: not informed\                        Tegafur 800mg (PO) D1-14\                                        G1 = 1.5%\
                                Oropharyngeal and hypopharyngeal carcinoma     Leucovorin 60mg (PO) D1-14                                       G2 = 15.4%\
                                                                                                                                                G3 = 73.8%\
                                                                                                                                                G4 = 6.2%

  Aapro et al.,([@B16])         1\. Renal carcinoma = 274 patients\            Everolimus                                                       1\. G1-G4 = 44%\
                                2. Neuroendocrine tumors = 204 patients\                                                                        2. G1-G4 = 64%\
                                3. Breast cancer = 482 patients\                                                                                3. G1-G4 = 59%
                                Mean age: not informed                                                                                          

  Tao et al.,([@B17])           34 patients\                                   Cisplatin\                                                       G0 = 0\
                                Mean age: 16 years\                            5-FU\                                                            G1 = 10 (29.4%)\
                                Nasopharyngeal carcinoma                       Radiation therapy                                                G2 = 14 (41.2%)\
                                                                                                                                                G3 = 9 (26.5%)\
                                                                                                                                                G4 = 1 (2.9%)

  Lin et al.,([@B18])           124 patients\                                  3 cycles\                                                        1\. G0 = 82\
                                Mean age: 42 years\                            5-FU 750mg/m^2^ D1-5\                                            G1 and 2 = 42\
                                Nasopharyngeal carcinoma                       Radiation therapy                                                G3 and 4 = 0\
                                                                                                                                                2. G0 = 58\
                                                                                                                                                G1 and 2 = 43\
                                                                                                                                                G3 and 4 = 14\
                                                                                                                                                3. G0 = 0\
                                                                                                                                                G1 and 2 = 64\
                                                                                                                                                G3 and 4 = 60

  Iwata et al.,([@B19])         51 patients\                                   Lapatinib 1,250mg qd\                                            G0 = 30 (59%)\
                                Mean age: 55 years\                            Capecitabine 1,000mg/m^2^ bid                                    G1 = 21 (41%)\
                                Breast cancer                                                                                                   G2 = 0\
                                                                                                                                                G3 = 0\
                                                                                                                                                G4 = 0

  Palappallil et al.,([@B20])   1\. 50 patients\                               1\. FAC\                                                         1\. G1-G4 = 45 (90%)\
                                2. 50 patients\                                5-FU 500mg/m^2^\                                                 2. G1-G4 = 2 (4%)
                                Mean age: 45 (20-70) years\                    Doxorubicin 50mg/m^2^\                                           
                                Breast cancer                                  Cyclophosphamide 500mg/m^2^\                                     
                                                                               2. AC-P\                                                         
                                                                               Doxorubicin 60mg/m^2^\                                           
                                                                               Cyclophosphamide 600mg/m^2^\                                     
                                                                               Paclitaxel 175mg/m^2^                                            

  Baird et al.,([@B21])         1\. 200 patients\                              1\. CAPOX 2000\                                                  1\. G1 = 22 (11%)\
                                2. 200 patients\                               Capecitabine 2,000mg/m^2^ D1-14\                                 G2 = 5 (2.5%)\
                                Mean age: 65 years\                            Oxaliplatin 130mg/m^2^ D1\                                       G3 = 0 (0%)\
                                Colorectal carcinoma                           2. CAPOX 1.700\                                                  G4 = 0 (0%)\
                                                                               Capecitabine 1,700mg/m^2^ D1-14\                                 2. G1 = 22 (11%)\
                                                                               Oxaliplatin 130mg/m^2^ D1\                                       G2 = 5 (2.5%)\
                                                                               Cetuximab                                                        G3 = 2 (1%)\
                                                                                                                                                G4 = 0 (0%)

  Lee et al.,([@B22])           32 patients\                                   Capecitabine 2,000mg/m^2^ D1-14\                                 G1-G2 = 4 (12.9%)\
                                Mean age: 53 years\                            Cisplatin 60mg/m^2^ D1                                           G3-G4 = 1 (3.2%)
                                Colorectal carcinoma                                                                                            

  Abromowitch et al.,([@B23])   1\. 85 patients\                               1\. Induction\                                                   1\. Induction\
                                2. 82 patients\                                Vincristine 1.5mg/m^2^ D0, 7 and 14\                             G1-G4 = 0 (0%)\
                                3.1. 76 patients\                              Daunomycin 60mg/m^2^ D1 and 2\                                   2. Consolidation\
                                3.2. 73 patients\                              Cyclophosphamide 1,200mg/m^2^ D0\                                G1-G4 = 5 (6.1%)\
                                3.3. 70 patients\                              L-Asparaginase\                                                  3. Maintenance\
                                3.4. 68 patients\                              2. Consolidation\                                                3.1 G1-G4 = 3 (3.9%)\
                                3.5. 65 patients\                              Vincristine 1.5mg/m^2^ D0 and 7\                                 3.2 G1-G4 = 6 (8.2%)\
                                3.6. 65 patients\                              Cytarabine 2,000mg/m^2^ D0 and 1\                                3.3 G1-G4 = 2 (2.9%)\
                                Mean age: 5.1 years\                           Etoposide 200mg/m^2^ D0 and 1\                                   3.4 G1-G4 = 3 (4.4%)\
                                Lymphoblastic leukemia                         Tioguanine 300mg/m^2^ D0-3\                                      3.5 G1-G4 = 1 (1.5%)\
                                                                               Methotrexate 1,000mg/m^2^ (IV)\                                  3.6 G1-G4 = 4 (6.2%)
                                                                               3. Maintenance\                                                  
                                                                               Cyclophosphamide 1,200mg/m^2^ D0\                                
                                                                               Tioguanine 300mg/m^2^ D0-3\                                      
                                                                               Vincristine 15mg/m^2^ D14 and 21\                                
                                                                               Doxorubicin 30mg/m^2^ D14\                                       
                                                                               Cyclophosphamide 1,200mg/m^2^ D0\                                
                                                                               Vincristine 15mg/m^2^ D28\                                       
                                                                               Methotrexate 1,000mg/m^2^ (IV)                                   

  Shin et al.,([@B24])          17 patients\                                   CHOP\                                                            G0 = 10 (58.84%)\
                                Mean age: 38 years\                            Cyclophosphamide 750mg/m^2^ D1\                                  G1 = 2 (11.76%)\
                                Hemophagocytic lymphohistiocytosis             Doxorubicin 50mg/m^2^ D1\                                        G2 = 2 (11.76%)\
                                                                               Vincristine 1.4mg/m^2^ D1\                                       G3 = 3 (17.64%)\
                                                                               Prednisone 40mg/m^2^ D1-5                                        G4 = 0

  Blijlevens et al.,([@B25])    1\. 109 patients with multiple myeloma\        1\. Melphalan 200mg/m^2^\                                        1\. G0 = 10%\
                                Mean age: 56.8 years\                          2. BEAM\                                                         G1-G2 = 44 %\
                                2. 88 patients with non-Hodgkin\'s lymphoma\   Carmustine 300mg/m^2^\                                           G3-G4 = 46%\
                                Mean age: 50 years                             Etoposide 800mg/m^2^\                                            2. G0 = 17%\
                                                                               Cytarabine 800-1,600mg/m^2^\                                     G1-G2 = 41%\
                                                                               Melphalan 140mg/m^2^                                             G3-G4 = 42%

  Fadda et al.,([@B26])         231 patients before HSCT\                      Alkylating agents\                                               1\. Melphalan\
                                Mean age: 7.6 years                            1. Melphalan\                                                    G0 = 20\
                                                                               2. Busulfan\                                                     G1-G4 = 24\
                                                                               3. Others                                                        2. Busulfan\
                                                                                                                                                G0 = 34\
                                                                                                                                                G1-G4 = 153\
                                                                                                                                                3. Others\
                                                                                                                                                G0 = 42\
                                                                                                                                                G1-G4 = 64

  Castagna et al.,([@B27])      1\. 29 patients\                               1\. Melphalan 200mg/m^2^ D1\                                     1\. Melphalan - G3-G4 = 17 (60%)\
                                2. 24 patients\                                2. BEAM\                                                         2. BEAM - G3-G4 = 12 (50%)
                                Mean age: 31 years\                            Carmustine 300mg/m^2^ D1\                                        
                                HSCT Hodgkin\'s lymphoma                       Etoposide 800mg/m^2^ D1-4\                                       
                                                                               Cytarabine 1,600mg/m^2^ D1-4\                                    
                                                                               Melphalan 140mg/m^2^ D1                                          

  Oh et al.,([@B28])            43 patients\                                   Docetaxel 70mg/m^2^\                                             G1 = 1 (2.3%)\
                                Mean age: 55 years\                            5-FU 1200mg/m^2^\                                                G2 = 1 (2.3%)\
                                Gastric carcinoma                              Cisplatin 40mg/m^2^                                              G3-G4 = 0 (0)

  Schmid et al.,([@B29])        93 patients\                                   1\. AT\                                                          1\. AT - G3-G4=4.6%\
                                1. 48\                                         Doxorubicin 60mg/m^2^\                                           2. HDCT - G3-G4 = 26.3%
                                2. 45\                                         Paclitaxel 200mg/m^2^\                                           
                                Mean age:\                                     2. HDCT\                                                         
                                1. 29 years\                                   Mitoxantrone 45mg/m^2^\                                          
                                2. 25 years\                                   Cyclophosphamide 2,400mg/m^2^\                                   
                                Breast cancer                                  Etoposide 2,500mg/m^2^                                           

  Saini et al.,([@B30])         716 patients\                                  1\. 5-FU 300mg/m^2^ IV continuous\                               1\. G3-G4 = 3.6%\
                                Mean age: 63 years\                            2. 5-FU 425mg/m^2^ bolus D1-5                                    2. G3-G4 = 19.6%
                                Colorectal carcinoma                                                                                            

  Kremens et al.,([@B31])       20 patients\                                   Melphalan 200mg/m^2^ D1-5\                                       G3-G4 = 10 (50%)
                                Mean age: 5.67 years\                          Etoposide\                                                       
                                Wilms tumor                                    Carboplatin                                                      

  Lacayo et al.,([@B32])        38 patients\                                   1\. DAT\                                                         1\. DAT - G3-G4 = 2 (13%)\
                                1. 15\                                         Daunomycin 45mg/m^2^ D1-3\                                       2. DAT + high doses cytarabine\
                                2. 23\                                         Cytarabine 100mg/m^2^ D1-7\                                      G3-G4 = 8 (35%)
                                Mean age: not informed\                        Tioguanine 100mg/m^2^ D1-7\                                      
                                Acute myeloid leukemia                         2. DAT + high doses cytarabine DAT\                              
                                                                               Cytarabine 1,000mg/m^2^ bid D1-7                                 

  Leblond et al.,([@B33])       1\. 46 patients\                               1\. FAMP\                                                        1\. FAMP - G1-G4=0\
                                2. 46 patients\                                Fludarabine 25mg/m^2^ D1-5\                                      2. CAP - G1-G4=10
                                Mean age: 64 years\                            2. CAP\                                                          
                                Waldenström macroglobulinemia                  Cyclophosphamide 750mg/m^2^ D1\                                  
                                                                               Doxorubicin 25mg/m^2^ D1\                                        
                                                                               Prednisone 40mg/m^2^ D1-5                                        

  Lissoni et al.,([@B34])       49 patients\                                   Epirubicin 70mg/m^2^\                                            G1 = 12\
                                Mean age: 53.7 years\                          Paclitaxel 175mg/m^2^\                                           G2 = 0\
                                Endometrial adenocarcinoma                     Cisplatin 70mg/m^2^                                              G3 = 0\
                                                                                                                                                G4 = 0

  Wang et al.,([@B35])          16 patients\                                   Cytarabine 3,000mg/m^2^ bid D1-4\                                G1 = 6\
                                Mean age: 42.7 years\                          Mitoxantrone 6mg/m^2^ D1-5                                       G2 = 2\
                                Refractory non-Hodgkin\'s lymphoma                                                                              G3 = 5\
                                                                                                                                                G4 = 1

  Anderson et al.,([@B36])      148 patients\                                  Doxorubicin 35mg/m^2^ D1\                                        1\. Bolus - G1-G4 = 24 (31%)\
                                1. Bolus = 78\                                 Etoposide 100mg/m^2^ D1-5\                                       2. Infusion - G1-G4 = 37 (53%)
                                2. Infusion = 70\                              Ifosfamide 5000mg/m^2^ D1                                        
                                Mean age: 61 years Small cell lung cancer                                                                       

  Bishop et al.,([@B37])        274 patients\                                  Daunorubicin 50mg/m^2^ D1-3\                                     G3-G4 = 26%
                                Mean age: not informed\                        Etoposide 75mg/m^2^ D1-7                                         
                                Acute non-lymphocytic leukemia                                                                                  

  Clavel et al.,([@B38])        1\. 93 patients\                               1\. CABO\                                                        1\. G3-G4 = 24%\
                                2. 92 patients\                                Cisplatin 50mg/m^2^ D4\                                          2. G3-G4 = 31
                                Mean age: 57.5 years\                          Methotrexate 40mg/m^2^ D1 and 15\                                
                                Head and neck cancer                           Vincristine 2mg/m^2^ D1, 8 and 15\                               
                                                                               Bleomycin 10mg/m^2^ D1, 8 and 15\                                
                                                                               2. ABO\                                                          
                                                                               Methotrexate 40mg/m^2^ D1, 8 and 15\                             
                                                                               Vincristine 2mg/m^2^ D1, 8 and 15\                               
                                                                               Bleomycin 10mg/m^2^ D1, 8 and 15                                 
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IV: intravenous; D: day; 5-FU: 5-fluorouracil; G: grade; FOLFOX: oxaliplatin, 5-fluorouracil and leucovorin; mFOLFOX: FOLFOX with different dosage; PO: *per oris*; FAC: 5-FU, doxorubicin and cyclophosphamide; ACP: doxorubicin, cyclophosphamide and paclitaxel; CAPOX: capecitabine and oxiplatin; CHOP: cyclophosphamide, doxorubicin, vincristine and prednisone; BEAM: carmustine, etoposide, cytarabine and melphalan; HSCT: hematopoietic stem cell transplantation; AT: doxorubicin and paclitaxel; HDCT: mitoxantrone, cyclophosphamide and etoposide; DAT: daunorubicin, cytarabine and tioguanine; FAMP: fludarabine; CABO: cisplatin, methotrexate, vincristine and bleomycin; ABO: methotrexate, vincristine and bleomycin.

Most of the studies looked at protocols for treating carcinoma 16 (61.53%), 6 (23.07%) addressed therapy for hematological malignancies and 4 (15.4%) for hematopoietic stem cell transplantation (HSCT) ([Figure 1](#f1){ref-type="fig"}).

![Distribution of articles according to type of treatment\
HSCT: hematopoietic stem cell transplantation.](1679-4508-eins-16-01-eRW4007-gf01){#f1}

In the carcinoma protocols, treatments with chemotherapeutic agents, such as 5-fluorouracil (5-FU) and platinum derivatives lead to more frequent and severe cases of OM between cycles -- however, numbers varied. The use of 5-FU was strongly associated with the development of OM, according to Palappallil et al.^(^ [@B20] ^)^ The authors demonstrated that 90% of patients developed OM after using 5-FU. Bolus administration of said agent also showed higher toxicity (19.6% of patients with OM) than continuous infusion (3.6% of patients with OM). For chemotherapeutics, such as ifosfamide and doxorubicin, greater severity of OM (53% of patients) was observed in individuals receiving continuous infusion.

Four articles (15.4%) addressed conditioning regimens for HSCT. Two of them compared the use of melphalan with the BEAM protocol (carmustine, etoposide, cytarabine and melphalan). The incidence of severe OM with melphalan was 46% in one study^(^ [@B25] ^)^ and 60% in another.^(^ [@B27] ^)^ The BEAM protocol also showed high incidence of severe OM in both studies (42% and 50%). This same incidence of MO with the use of melphalan was also verified by Kremens et al.,^(^ [@B31] ^)^ (50%) and by Fadda et al.,^(^ [@B26] ^)^ (54.4%). These two authors also found a high incidence of OM among patients receiving busulfan (81.82%).

Of the 26 articles, 6 (23.07%) reported cases of MO after treatment of hematological malignancies. During the induction phase for leukemia, no patients had OM; in the consolidation phase, 6.1% had OM; and in the maintenance phase, the highest rate was 8.2%. When assessing the chemotherapeutic agents used, we observed that 26% of patients on daunorubicin and etoposide, and 37.5% of patients on high-dose cytarabine had severe OM. Another protocol studied was cyclophosphamide, doxorubicin, vincristine and prednisone CHOP, and of the 17 patients treated, 7 (41.16%) had some degree of OM.

DISCUSSION
==========

Oral mucositis is an adverse effect of anticancer therapy that, in addition to causing discomfort/pain, may affect the nutritional health of patients. Thus, it is increasingly important to know how these lesions behave in order to provide effective prevention and treatment. Understanding the effects of chemotherapy protocols that lead to greater oral toxicity is therefore necessary.

Of the articles reviewed, it is interesting to note that only two focused on evaluating oral toxicity resulting from the anticancer agent of choice. Most of them aimed to show the response to oncological treatment using certain chemotherapy protocols, and reporting of OM was limited to the occurrence of the condition.

The mean age of subjects was 43.54 years. This mean age reflects the fact that most studies addressed treatments for carcinoma, which is more common in adults.

In this review, many articles described the effects of chemotherapy protocols for treatment of different types of carcinoma, particularly protocols based on the use of 5-FU and platinum derivatives (cisplatin and oxyplatin).^(^ [@B13] ^-^ [@B18] ^,^ [@B20] ^-^ [@B22] ^,^ [@B28] ^,^ [@B30] ^,^ [@B34] ^)^ In these articles, the incidence of OM varied a great deal, but we identified that patients who received cisplatin had more severe OM.^(^ [@B15] ^-^ [@B17] ^)^

In the study by Lin et al.,^(^ [@B18] ^)^ oral toxicity worsened with each subsequent cycle. Patients received three cycles of the same chemotherapy protocol, and in the first cycle, only 33.87% of patients developed OM - all cases were mild (grades 1 and 2). In the second cycle, 49.57% developed some degree of OM, and 12.18% were severe. In the third cycle, 100% of patients developed OM, of which 48.38% were grades 3 and 4. We found no evidence in the literature that OM has a cumulative effect with cycles, but in this review the increase in OM severity over the course of treatment was significant.

Palappallil et al.,^(^ [@B20] ^)^ proposed a comparison between two different protocols for treating breast carcinoma. In both protocols, patients received cyclophosphamide and doxorubicin but, in the first protocol, 5-FU was also administered. As much as 90% of patients who received 5-FU developed some degree of OM, against only 4% of the remaining patients, which corroborates the oral toxicity of 5-FU. Administration of 5-FU was studied by Saini et al.,^(^ [@B30] ^)^ in 716 patients with colorectal carcinoma. Only 3.6% of those who received continuous infusions of the antineoplastic drug had severe OM, whereas 19.6% of patients who received bolus infusions of 5-FU had severe OM, which implies that oral toxicity is higher when the agent is administered as a bolus. Anderson et al.,^(^ [@B36] ^)^ also observed the mode of administration of antineoplastic agents ifosfamide and doxorubicin. Differently from Saini et al.,^(^ [@B30] ^)^ they observed a higher incidence of OM in patients who received continuous administration (53%). Only 31% of patients who received doxorubicin and ifosfamide by bolus administration had some degree of OM.

The oral toxicity associated with conditioning regimens for HSCT is already well documented in the literature.^(^ [@B3] ^,^ [@B25] ^-^ [@B27] ^,^ [@B31] ^,^ [@B39] ^)^ Despite the high incidence and the fact that oral damage caused by treatment regimens used in HSCT has prevention and treatment protocols guided by the MASCC/ISOO,^(^ [@B12] ^)^ there are still very few studies focusing on the effects of chemotherapeutics on the oral cavity. In this review, four articles^(^ [@B25] ^-^ [@B27] ^,^ [@B31] ^)^ addressing said protocols were selected. Blijlevens et al.,^(^ [@B25] ^)^ and Castagna et al.,^(^ [@B27] ^)^ compared the use of melphalan and the BEAM protocol as conditioning regimens for HSCT. Both found a high incidence of OM in association with both protocols, however it was slightly higher in patients submitted to conditioning with melphalan. The two papers found that, for both protocols, approximately 50% of patients developed severe OM. This demonstrates the marked oral toxicity resulting from HSCT conditioning. Kremens et al.,^(^ [@B31] ^)^ also demonstrated a high incidence of severe MO (50%) in patients on HSCT conditioning with melphalan for Wilms tumor, despite the small sample of only 20 subjects. Still on HSCT conditioning, Fadda et al.,^(^ [@B26] ^)^ looked at the effects of chemotherapeutics melphalan and busulfan and found that, of the patients receiving melphalan, 54.54% had some degree of OM, as described in previous studies. And as much as 81.82% of patients who received busulfan developed OM. Alkylating agents are known to form inter-filamentous bonds with DNA, *i.e* since DNA alkylation requires more complex repair mechanisms and may even inhibit DNA replication. This group of patients is often associated with the development of OM.^(^ [@B3] ^,^ [@B39] ^)^

Few studies have demonstrated the relation between chemotherapy protocols used in hematological malignancies and OM severity. Abromowitch et al.,^(^ [@B23] ^)^ demonstrated toxicity resulting from each phase of leukemia treatment. No significant oral toxicities were reported, with no patient developing OM on induction, 6.1% presenting on consolidation, and less than 10% on maintenance phases. The incidence found by those authors is too low when compared with other studies. Bishop et al.,^(^ [@B37] ^)^ studied leukemia treatment with daunorubicin and etoposide (drugs used for induction and consolidation) and found that 26% of patients developed severe OM, *i.e* than that reported by Abromowitch et al.,^(^ [@B23] ^)^ Among studies addressing leukemia treatments, Lacayo et al.,^(^ [@B32] ^)^ assessed protocols with and without high-dose cytarabine for patients with acute myeloid leukemia. Patients who received high doses of cytarabine had significantly higher rates of severe OM. Wang et al.,^(^ [@B35] ^)^ also analyzed a chemotherapy protocol based on highdose cytarabine for treating refractory non-Hodgkin lymphoma. Although the number of patients enrolled was not very expressive (n=16), 37.5% of subjects had severe OM. This review also included another study by Shin et al.,^(^ [@B24] ^)^ with a small number of patients, assessing cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) protocol in 17 patients with hemophagocytic lymphohistiocytosis; of those, seven patients developed some degree of OM.

CONCLUSION
==========

Although oral mucositis affects not only the patient\'s quality of life but also the course of antineoplastic treatment, few studies focused on the relation between the chemotherapy protocol and the incidence of the condition. In this review, we observed there are scarce studies assessing the relation between oral mucositis and the chemotherapy protocol used.

Through this integrative review, we further corroborate what has been frequently demonstrated in the literature: protocols for hematopoietic stem cell transplantation entail a high risk for development of oral mucositis. We also found that cytarabine, high-dose 5-FU, alkylating agents and platinum-based compounds are commonly associated with the development of oral mucositis. Therefore, when using the aforementioned protocols, attention must be paid to prevention and treatment of this condition. In addition, it is clear that further investigations are needed concerning the oral toxicity of different drugs, to allow for more effective prevention of this condition.
